Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates

Company Performance - Curis reported a quarterly loss of $1.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.14, but an improvement from a loss of $2.05 per share a year ago, indicating a surprise of -9.65% [1] - The company posted revenues of $2.38 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 11.74% and showing an increase from $2.09 million in the same quarter last year [2] - Curis has surpassed consensus EPS estimates two times over the last four quarters and has topped consensus revenue estimates four times during the same period [2] Stock Outlook - Curis shares have declined approximately 19.9% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.76 on revenues of $2.6 million, and for the current fiscal year, it is -$2.72 on revenues of $11.13 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Curis belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]